Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
Saini P, Adeniji OS, Bordoloi D, Kinslow J, Martinson J, Parent DM, Hong KY, Koshy J, Kulkarni AJ, Zilberstein NF, Balk RA, Moy JN, Giron LB, Tracy RP, Keshavarzian A, Muthumani K, Landay A, Weiner DB, Abdel-Mohsen M. Saini P, et al. Among authors: kulkarni aj. mBio. 2023 Feb 28;14(1):e0339322. doi: 10.1128/mbio.03393-22. Epub 2023 Feb 2. mBio. 2023. PMID: 36728420 Free PMC article.
Erratum for Adeniji et al., "COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions".
Adeniji OS, Giron LB, Purwar M, Zilberstein NF, Kulkarni AJ, Shaikh MW, Balk RA, Moy JN, Forsyth CB, Liu Q, Dweep H, Kossenkov A, Weiner DB, Keshavarzian A, Landay A, Abdel-Mohsen M. Adeniji OS, et al. Among authors: kulkarni aj. mBio. 2021 Jun 29;12(3):e0124421. doi: 10.1128/mBio.01244-21. Epub 2021 Jun 8. mBio. 2021. PMID: 34098736 Free PMC article. No abstract available.
Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein.
Bordoloi D, Xu Z, Ho M, Purwar M, Bhojnagarwala P, Cassel J, Giron LB, Walker S, Kulkarni AJ, Ruiz ET, Choi J, Zaidi FI, Wu Y, Wang S, Patel A, Ramos S, Smith T, Kulp D, Ugen KE, Srinivasan A, Abdel-Mohsen M, Humeau L, Weiner DB, Muthumani K. Bordoloi D, et al. Among authors: kulkarni aj. ACS Pharmacol Transl Sci. 2021 Jul 29;4(4):1349-1361. doi: 10.1021/acsptsci.1c00058. eCollection 2021 Aug 13. ACS Pharmacol Transl Sci. 2021. PMID: 34396059 Free PMC article.
Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity.
Choi H, Ho M, Adeniji OS, Giron L, Bordoloi D, Kulkarni AJ, Puchalt AP, Abdel-Mohsen M, Muthumani K. Choi H, et al. Among authors: kulkarni aj. Front Oncol. 2021 Nov 19;11:778989. doi: 10.3389/fonc.2021.778989. eCollection 2021. Front Oncol. 2021. PMID: 34869028 Free PMC article.
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, Reuschel EL, Purwar M, Christensen-Quick A, Liu N, Andrade VM, Diehl MC, Wani S, Lupicka M, Sylvester A, Morrow MP, Pezzoli P, McMullan T, Kulkarni AJ, Zaidi FI, Frase D, Liaw K, Smith TRF, Ramos SJ, Ervin J, Adams M, Lee J, Dallas M, Shah Brown A, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM, Boyer JD, Mammen MP. Kraynyak KA, et al. Among authors: kulkarni aj. J Infect Dis. 2022 Jun 1;225(11):1923-1932. doi: 10.1093/infdis/jiac016. J Infect Dis. 2022. PMID: 35079784 Free PMC article. Clinical Trial.
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
Walters JN, Schouest B, Patel A, Reuschel EL, Schultheis K, Parzych E, Maricic I, Gary EN, Purwar M, Andrade VM, Doan A, Elwood D, Eblimit Z, Nguyen B, Frase D, Zaidi FI, Kulkarni A, Generotti A, Joseph Kim J, Humeau LM, Ramos SJ, Smith TRF, Weiner DB, Broderick KE. Walters JN, et al. Vaccine. 2022 May 9;40(21):2960-2969. doi: 10.1016/j.vaccine.2022.03.060. Epub 2022 Apr 4. Vaccine. 2022. PMID: 35428500 Free PMC article.
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2.
Parzych EM, Du J, Ali AR, Schultheis K, Frase D, Smith TRF, Cui J, Chokkalingam N, Tursi NJ, Andrade VM, Warner BM, Gary EN, Li Y, Choi J, Eisenhauer J, Maricic I, Kulkarni A, Chu JD, Villafana G, Rosenthal K, Ren K, Francica JR, Wootton SK, Tebas P, Kobasa D, Broderick KE, Boyer JD, Esser MT, Pallesen J, Kulp DW, Patel A, Weiner DB. Parzych EM, et al. Nat Commun. 2022 Oct 6;13(1):5886. doi: 10.1038/s41467-022-33309-6. Nat Commun. 2022. PMID: 36202799 Free PMC article.
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape.
Park DH, Liaw K, Bhojnagarwala P, Zhu X, Choi J, Ali AR, Bordoloi D, Gary EN, O'Connell RP, Kulkarni A, Guimet D, Smith T, Perales-Puchalt A, Patel A, Weiner DB. Park DH, et al. Mol Ther Oncolytics. 2023 Feb 16;28:249-263. doi: 10.1016/j.omto.2023.02.004. eCollection 2023 Mar 16. Mol Ther Oncolytics. 2023. PMID: 36915911 Free PMC article.
27 results